Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Account Payables (2016 - 2025)

Neuroone Medical Technologies' Change in Account Payables history spans 9 years, with the latest figure at -$439992.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 2845.26% year-over-year to -$439992.0; the TTM value through Dec 2025 reached -$185070.0, down 573.64%, while the annual FY2025 figure was $239983.0, 258.22% up from the prior year.
  • Change in Account Payables reached -$439992.0 in Q4 2025 per NMTC's latest filing, down from $526943.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $602635.0 in Q3 2022 to a low of -$439992.0 in Q4 2025.
  • Average Change in Account Payables over 5 years is $1396.8, with a median of -$18435.0 recorded in 2021.
  • The largest YoY upside for Change in Account Payables was 3746.27% in 2025 against a maximum downside of 2845.26% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $291172.0 in 2021, then crashed by 152.92% to -$154098.0 in 2022, then skyrocketed by 151.61% to $79527.0 in 2023, then tumbled by 118.78% to -$14939.0 in 2024, then tumbled by 2845.26% to -$439992.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Change in Account Payables are -$439992.0 (Q4 2025), $526943.0 (Q3 2025), and -$367845.0 (Q2 2025).